Neurobiological links between depression and AD: The role of TGF-β1 signaling as a new pharmacological target

Filippo Caraci, Simona Federica Spampinato, Maria Grazia Morgese, Fabio Tascedda, Maria Grazia Salluzzo, Maria Concetta Giambirtone, Giuseppe Caruso, Antonio Munafò, Sebastiano Alfio Torrisi, Gian Marco Leggio, Luigia Trabace, Ferdinando Nicoletti, Filippo Drago, Maria Angela Sortino, Agata Copani

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

In the last several years a large number of studies have demonstrated the neurobiological and clinical continuum between depression and Alzheimer's disease (AD). Depression is a risk factor for the development of AD, and the presence of depressive symptoms significantly increases the conversion of Mild Cognitive Impairment (MCI) into AD. Common pathophysiological events have been identified in depression and AD, including neuroinflammation with an aberrant Tumor Necrosis Factor-α (TNF-α) signaling, and an impairment of Brain-Derived Neurotrophic Factor (BDNF) and Transforming-Growth-Factor-β1 (TGF-β1) signaling.TGF-β1 is an anti-inflammatory cytokine that exerts neuroprotective effects against amyloid-β (Aβ)-induced neurodegeneration, and it has a key role in memory formation and synaptic plasticity. TGF-β1 plasma levels are reduced in major depressed patients (MDD), correlate with depression severity, and significantly contribute to treatment resistance in MDD. The deficit of Smad-dependent TGF-β1 signaling is also an early event in AD pathogenesis, which contributes to inflammaging and cognitive decline in AD. A long-term treatment with antidepressants such as selective-serotonin-reuptake inhibitors (SSRIs) is known to reduce the risk of AD in patients with depression and, SSRIs, such as fluoxetine, increase the release of TGF-β1 from astrocytes and exert relevant neuroprotective effects in experimental models of AD.We propose the TGF-β1 signaling pathway as a common pharmacological target in depression and AD, and discuss the potential rescue of TGF-β1 signaling by antidepressants as a way to prevent the transition from depression to AD.

Original languageEnglish
JournalPharmacological Research
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Transforming Growth Factors
Alzheimer Disease
Pharmacology
Depression
Serotonin Uptake Inhibitors
Neuroprotective Agents
Antidepressive Agents
Neuronal Plasticity
Fluoxetine
Brain-Derived Neurotrophic Factor
Amyloid
Astrocytes
Anti-Inflammatory Agents
Theoretical Models
Tumor Necrosis Factor-alpha
Cytokines

Keywords

  • Alzheimer's disease
  • Amyloid-β
  • Antidepressants
  • Depression
  • Transforming-Growth-Factor-β1

ASJC Scopus subject areas

  • Pharmacology

Cite this

Neurobiological links between depression and AD : The role of TGF-β1 signaling as a new pharmacological target. / Caraci, Filippo; Spampinato, Simona Federica; Morgese, Maria Grazia; Tascedda, Fabio; Salluzzo, Maria Grazia; Giambirtone, Maria Concetta; Caruso, Giuseppe; Munafò, Antonio; Torrisi, Sebastiano Alfio; Leggio, Gian Marco; Trabace, Luigia; Nicoletti, Ferdinando; Drago, Filippo; Sortino, Maria Angela; Copani, Agata.

In: Pharmacological Research, 01.01.2018.

Research output: Contribution to journalArticle

Caraci, F, Spampinato, SF, Morgese, MG, Tascedda, F, Salluzzo, MG, Giambirtone, MC, Caruso, G, Munafò, A, Torrisi, SA, Leggio, GM, Trabace, L, Nicoletti, F, Drago, F, Sortino, MA & Copani, A 2018, 'Neurobiological links between depression and AD: The role of TGF-β1 signaling as a new pharmacological target', Pharmacological Research. https://doi.org/10.1016/j.phrs.2018.02.007
Caraci, Filippo ; Spampinato, Simona Federica ; Morgese, Maria Grazia ; Tascedda, Fabio ; Salluzzo, Maria Grazia ; Giambirtone, Maria Concetta ; Caruso, Giuseppe ; Munafò, Antonio ; Torrisi, Sebastiano Alfio ; Leggio, Gian Marco ; Trabace, Luigia ; Nicoletti, Ferdinando ; Drago, Filippo ; Sortino, Maria Angela ; Copani, Agata. / Neurobiological links between depression and AD : The role of TGF-β1 signaling as a new pharmacological target. In: Pharmacological Research. 2018.
@article{77017bb07bc94c78a06d786260b12e3a,
title = "Neurobiological links between depression and AD: The role of TGF-β1 signaling as a new pharmacological target",
abstract = "In the last several years a large number of studies have demonstrated the neurobiological and clinical continuum between depression and Alzheimer's disease (AD). Depression is a risk factor for the development of AD, and the presence of depressive symptoms significantly increases the conversion of Mild Cognitive Impairment (MCI) into AD. Common pathophysiological events have been identified in depression and AD, including neuroinflammation with an aberrant Tumor Necrosis Factor-α (TNF-α) signaling, and an impairment of Brain-Derived Neurotrophic Factor (BDNF) and Transforming-Growth-Factor-β1 (TGF-β1) signaling.TGF-β1 is an anti-inflammatory cytokine that exerts neuroprotective effects against amyloid-β (Aβ)-induced neurodegeneration, and it has a key role in memory formation and synaptic plasticity. TGF-β1 plasma levels are reduced in major depressed patients (MDD), correlate with depression severity, and significantly contribute to treatment resistance in MDD. The deficit of Smad-dependent TGF-β1 signaling is also an early event in AD pathogenesis, which contributes to inflammaging and cognitive decline in AD. A long-term treatment with antidepressants such as selective-serotonin-reuptake inhibitors (SSRIs) is known to reduce the risk of AD in patients with depression and, SSRIs, such as fluoxetine, increase the release of TGF-β1 from astrocytes and exert relevant neuroprotective effects in experimental models of AD.We propose the TGF-β1 signaling pathway as a common pharmacological target in depression and AD, and discuss the potential rescue of TGF-β1 signaling by antidepressants as a way to prevent the transition from depression to AD.",
keywords = "Alzheimer's disease, Amyloid-β, Antidepressants, Depression, Transforming-Growth-Factor-β1",
author = "Filippo Caraci and Spampinato, {Simona Federica} and Morgese, {Maria Grazia} and Fabio Tascedda and Salluzzo, {Maria Grazia} and Giambirtone, {Maria Concetta} and Giuseppe Caruso and Antonio Munaf{\`o} and Torrisi, {Sebastiano Alfio} and Leggio, {Gian Marco} and Luigia Trabace and Ferdinando Nicoletti and Filippo Drago and Sortino, {Maria Angela} and Agata Copani",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.phrs.2018.02.007",
language = "English",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press",

}

TY - JOUR

T1 - Neurobiological links between depression and AD

T2 - The role of TGF-β1 signaling as a new pharmacological target

AU - Caraci, Filippo

AU - Spampinato, Simona Federica

AU - Morgese, Maria Grazia

AU - Tascedda, Fabio

AU - Salluzzo, Maria Grazia

AU - Giambirtone, Maria Concetta

AU - Caruso, Giuseppe

AU - Munafò, Antonio

AU - Torrisi, Sebastiano Alfio

AU - Leggio, Gian Marco

AU - Trabace, Luigia

AU - Nicoletti, Ferdinando

AU - Drago, Filippo

AU - Sortino, Maria Angela

AU - Copani, Agata

PY - 2018/1/1

Y1 - 2018/1/1

N2 - In the last several years a large number of studies have demonstrated the neurobiological and clinical continuum between depression and Alzheimer's disease (AD). Depression is a risk factor for the development of AD, and the presence of depressive symptoms significantly increases the conversion of Mild Cognitive Impairment (MCI) into AD. Common pathophysiological events have been identified in depression and AD, including neuroinflammation with an aberrant Tumor Necrosis Factor-α (TNF-α) signaling, and an impairment of Brain-Derived Neurotrophic Factor (BDNF) and Transforming-Growth-Factor-β1 (TGF-β1) signaling.TGF-β1 is an anti-inflammatory cytokine that exerts neuroprotective effects against amyloid-β (Aβ)-induced neurodegeneration, and it has a key role in memory formation and synaptic plasticity. TGF-β1 plasma levels are reduced in major depressed patients (MDD), correlate with depression severity, and significantly contribute to treatment resistance in MDD. The deficit of Smad-dependent TGF-β1 signaling is also an early event in AD pathogenesis, which contributes to inflammaging and cognitive decline in AD. A long-term treatment with antidepressants such as selective-serotonin-reuptake inhibitors (SSRIs) is known to reduce the risk of AD in patients with depression and, SSRIs, such as fluoxetine, increase the release of TGF-β1 from astrocytes and exert relevant neuroprotective effects in experimental models of AD.We propose the TGF-β1 signaling pathway as a common pharmacological target in depression and AD, and discuss the potential rescue of TGF-β1 signaling by antidepressants as a way to prevent the transition from depression to AD.

AB - In the last several years a large number of studies have demonstrated the neurobiological and clinical continuum between depression and Alzheimer's disease (AD). Depression is a risk factor for the development of AD, and the presence of depressive symptoms significantly increases the conversion of Mild Cognitive Impairment (MCI) into AD. Common pathophysiological events have been identified in depression and AD, including neuroinflammation with an aberrant Tumor Necrosis Factor-α (TNF-α) signaling, and an impairment of Brain-Derived Neurotrophic Factor (BDNF) and Transforming-Growth-Factor-β1 (TGF-β1) signaling.TGF-β1 is an anti-inflammatory cytokine that exerts neuroprotective effects against amyloid-β (Aβ)-induced neurodegeneration, and it has a key role in memory formation and synaptic plasticity. TGF-β1 plasma levels are reduced in major depressed patients (MDD), correlate with depression severity, and significantly contribute to treatment resistance in MDD. The deficit of Smad-dependent TGF-β1 signaling is also an early event in AD pathogenesis, which contributes to inflammaging and cognitive decline in AD. A long-term treatment with antidepressants such as selective-serotonin-reuptake inhibitors (SSRIs) is known to reduce the risk of AD in patients with depression and, SSRIs, such as fluoxetine, increase the release of TGF-β1 from astrocytes and exert relevant neuroprotective effects in experimental models of AD.We propose the TGF-β1 signaling pathway as a common pharmacological target in depression and AD, and discuss the potential rescue of TGF-β1 signaling by antidepressants as a way to prevent the transition from depression to AD.

KW - Alzheimer's disease

KW - Amyloid-β

KW - Antidepressants

KW - Depression

KW - Transforming-Growth-Factor-β1

UR - http://www.scopus.com/inward/record.url?scp=85041907216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041907216&partnerID=8YFLogxK

U2 - 10.1016/j.phrs.2018.02.007

DO - 10.1016/j.phrs.2018.02.007

M3 - Article

AN - SCOPUS:85041907216

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

ER -